Merck’s Vorapaxar Overcomes Trial Questions, Committee Recommends Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Cardiovascular and Renal Drugs Advisory Committee says that TRA2P trial’s interim analysis issues did not affect interpretation of its results.
You may also be interested in...
FDA Reviewers Say Vorapaxar Approvable, But Question Study Changes
As the platelet inhibitor heads to an advisory committee, agency reviewers raise issues about safety-based changes to its Phase III trials.
Bleeding Rates In TRA-2P Further Dim Outlook For Merck’s Vorapaxar
Outcomes study of about 25,000 patients shows novel antiplatelet drug reduces events but also increases major bleeding, including intracranial hemorrhage.
US FDA’s Standard Application Assessment Makes A Comeback
After years where many more applications received priority assessments than standard assessments, in FY 2022 the difference narrowed.